CME Group (CME) News Today

CME Group Inc. (NASDAQ:CME) shares are trading higher amid a mix of favorable legal rulings, earnings beats and bullish analyst actions, despite some headwinds from rating downgrades and insider selling.

• Positive Sentiment: CME Group won a lawsuit brought by former floor traders after a jury rejected claims that the exchange operator breached its agreement when it transitioned to electronic markets. WSJ: CME Group Wins Lawsuit by Former Floor Traders
• Positive Sentiment: Oppenheimer boosted its price target on CME Group to $303.00 and maintained an “outperform” rating, signaling confidence in the stock’s upside potential. MarketBeat: Oppenheimer Increases CME Group Price Target
• Positive Sentiment: Morgan Stanley’s Michael Cyprys reiterated a Buy rating on CME Group, citing strong demand for risk management products and a solid financial position. TipRanks: Positive Outlook for CME Group
• Positive Sentiment: CME Group reported Q2 earnings of $2.96 EPS, beating consensus by $0.05, and revenue of $1.69 billion, slightly above estimates, with net margin up year-over-year. MarketBeat: CME Group Beats Q2 Estimates
• Neutral Sentiment: UBS Group reiterated a “neutral” rating and a $305.00 price target on CME Group shares, signaling a balanced view on near-term performance. MarketBeat: UBS Maintains Neutral on CME Group
• Neutral Sentiment: Analysts at seven firms shared mixed views on CME Group’s outlook in a recent survey, reflecting a range of price targets and ratings. Benzinga: Breaking Down CME Group
• Neutral Sentiment: A report showed short interest in CME Group shares holding steady, indicating no notable build-up of bearish bets despite market volatility.
• Neutral Sentiment: An article on Biodesix Inc. launching a CME-accredited education program (unrelated to CME Group) is drawing occasional ticker confusion but has no direct impact on the exchange operator’s fundamentals. InsiderMonkey: Biodesix, APAPP Partner on CME Education
• Negative Sentiment: Barclays trimmed its price target on CME Group shares to $298.00 and moved the rating to “equal weight,” reflecting more cautious expectations. MarketBeat: Barclays Lowers CME Group Price Target
• Negative Sentiment: UBS cut its view on CME Group over signs of a recent slowdown in trading activity, weighing on near-term growth prospects. MSN: CME Group Cut at UBS
• Negative Sentiment: Representative Jefferson Shreve sold between $15,001 and $50,000 of CME Group stock in mid-May, a move some investors view as a signal to take profits. MarketBeat: CME Group Shares Unloaded by Rep. Shreve